Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“In March 2025, Avenue received a "notice of intent to terminate" letter from AnnJi, the licensor of AJ201, with respect to the license agreement under which Avenue was granted rights to the product candidate.”
FILING10-K0001104659-26-037874cik 0001429260
“Amortization of acquired intangible assets increased by $0.8 million, or 24%, to $4.3 million for the year ended December 31, 2025, from $3.4 million for the year ended December 31, 2024, driven by the addition of the Emrosi acquired intangible asset upon Journey's payment to DRL of the milestone payment triggered by the FDA's approval of Emrosi in November 2024.”
FILING10-K0001104659-26-037874cik 0001429260
“On February 18, 2026, our partner company Avenue entered into a license agreement with Duke University ("Duke"), whereby Avenue obtained an exclusive worldwide license (the "ATX-04 License") from Duke to certain patents and know-how pertaining to clenbuterol for the treatment of lysosomal storage diseases.”
FILING10-K0001104659-26-037874cik 0001429260
“Our subsidiary, Cyprium, is eligible to receive commercial milestones and royalties on net sales of ZYCUBO from Sentynl, and was also transferred a Rare Pediatric Disease Priority Review Voucher ("PRV") from Sentynl subsequent to the approval, which was sold for $205 million in gross proceeds.”
FILING10-K0001104659-26-037874cik 0001429260
“On October 5, 2021, AstraZeneca acquired Caelum Biosciences, Inc. ("Caelum"), a former subsidiary of Fortress for an upfront payment of approximately $135 million paid to Caelum shareholders, of which approximately $56.9 million was paid to Fortress.”
FILING10-K0001104659-26-037874cik 0001429260
“In November 2025, Avenue announced it had entered into an agreement for Baergic to be acquired by Axsome, including the global rights to BAER-101 (also known as AZD7325), a novel oral GABAA α2,3 subtype-selective receptor positive allosteric modulator ("PAM").”
FILING10-K0001104659-26-037874cik 0001429260
“Under the Transaction Documents, Urica transferred substantially all intellectual property rights in dotinurad to Crystalys.”
FILING10-K0001104659-26-037874cik 0001429260
“JMC began supplying Amzeeq to Cutia in August 2025 under an agreement with Cutia.”
FILING10-K0001104659-26-037874cik 0001429260
“In December 2023, Cyprium completed the asset transfer of CUTX-101 to Sentynl.”
FILING10-K0001104659-26-037874cik 0001429260
“In May 2025, our former subsidiary, Checkpoint, was acquired by Sun Pharma for $4.10 per share in cash plus a contingent value right of up to $0.70 per share upon the achievement of EU approval of Checkpoint's principal drug product candidate.”
FILING10-K0001104659-26-037874cik 0001429260
“BAER-101 was originally licensed by Baergic from AstraZeneca AB and will be referred to as AXS-17 by Axsome going forward.”
FILING10-K0001104659-26-037874cik 0001429260
“The trial is funded by a grant from the National Cancer Institute ("NCI") (NCT06059391).”
FILING10-K0001104659-26-037874cik 0001429260
“In October 2014, we entered into an agreement (the Office Agreement) with Fortress Biotech, Inc. (FBIO) to occupy approximately 45% of the 24,000 square feet of New York City office space leased by FBIO.”
FILING10-K0001437749-26-006133cik 0001001316disclosed by TGTX
Watchlist prices, news filtered to it, and its next report on your desk.
Fortress Biotech, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 2.48 · gapped above the open, then crossed back over prior close. High/low 2.53 at 9:45 am ET, 2.47 at 3:30 pm ET.
Fortress Biotech, Inc. has 6 disclosed suppliers and 7 disclosed customers. Each one is named in an SEC filing, either Fortress Biotech, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
FBIO (Fortress Biotech, Inc.) has 6 disclosed suppliers and 7 disclosed customers, strongest disclosure first.
Suppliers:
Customers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: AXSM −5.64%, in healthcare.